Seed · Biotech · London, United Kingdom · Founded 2021 · 8–10 employees
Nuntius Therapeutics develops cell-specific mRNA, DNA and CRISPR therapies using proprietary dendrimer-lipid nanocarrier delivery technology that overcomes the challenge of delivering large genetic payloads to specific cells beyond the liver. The company leverages machine learning to screen over 4.5 million theoretical nanocarrier formulations to identify optimal candidates. In August 2024, they emerged from stealth with a collaboration agreement with Taiho Pharmaceutical for mRNA cancer immunotherapies. Their technology offers alternatives to traditional lipid nanoparticles and viral vectors with reduced immunogenicity risks.
No open roles listed right now.